Identifying relevant determinants of in-hospital time to diagnosis for ANCA-associated vasculitis patients
- PMID: 35784016
- PMCID: PMC9245319
- DOI: 10.1093/rap/rkac045
Identifying relevant determinants of in-hospital time to diagnosis for ANCA-associated vasculitis patients
Abstract
Objectives: Diagnosing patients with ANCA-associated vasculitis (AAV) can be challenging owing to its rarity and complexity. Diagnostic delay can have severe consequences, such as chronic organ damage or even death. Given that few studies have addressed diagnostic pathways to identify opportunities to improve, we performed a clinical audit to evaluate the diagnostic phase.
Methods: This retrospective, observational study of electronic medical records data in hospitals focused on diagnostic procedures during the first assessment until diagnosis.
Results: We included 230 AAV patients from nine hospitals. First assessments were mainly performed by a specialist in internal medicine (52%), pulmonology (14%), ENT (13%) or rheumatology (10%). The overall median time to diagnosis was 13 [interquartile range: 2-49] days, and in patients primarily examined by a specialist in internal medicine it was 6 [1-25] days, rheumatology 14 [4-45] days, pulmonology 15 [5-70] days and ENT 57 [16-176] days (P = 0.004). Twenty-two of 31 (71%) patients primarily assessed by a specialist in ENT had non-generalized disease, of whom 14 (64%) had ENT-limited activity. Two hundred and nineteen biopsies were performed in 187 patients (81%). Histopathological support for AAV was observed in 86% of kidney biopsies, 64% of lung biopsies and 34% of ENT biopsies.
Conclusion: In The Netherlands, AAV is diagnosed and managed predominantly by internal medicine specialists. Diagnostic delay was associated with non-generalized disease and ENT involvement at presentation. Additionally, ENT biopsies had a low diagnostic yield, in contrast to kidney and lung biopsies. Awareness of this should lead to more frequent consideration of AAV and early referral for a multidisciplinary approach when AAV is suspected.
Keywords: ANCA-associated vasculitis; diagnostic delay; health-care usage; patient trajectory; pauci-immune glomerulonephritis.
© The Author(s) 2022. Published by Oxford University Press on behalf of the British Society for Rheumatology.
Figures


Similar articles
-
Increased renal damage in hypocomplementemic patients with ANCA-associated vasculitis: retrospective cohort study.Clin Rheumatol. 2019 Oct;38(10):2819-2824. doi: 10.1007/s10067-019-04636-9. Epub 2019 Jun 20. Clin Rheumatol. 2019. PMID: 31222573
-
Complement in ANCA-associated glomerulonephritis.Nephrol Dial Transplant. 2017 Aug 1;32(8):1302-1313. doi: 10.1093/ndt/gfv288. Nephrol Dial Transplant. 2017. PMID: 26275893
-
Central Nervous System Involvement in ANCA-Associated Vasculitis: What Neurologists Need to Know.Front Neurol. 2019 Jan 10;9:1166. doi: 10.3389/fneur.2018.01166. eCollection 2018. Front Neurol. 2019. PMID: 30687221 Free PMC article. Review.
-
Renal function and ear, nose, throat involvement in anti-neutrophil cytoplasmic antibody-associated vasculitis: prospective data from the European Vasculitis Society clinical trials.Rheumatology (Oxford). 2015 May;54(5):899-907. doi: 10.1093/rheumatology/keu357. Epub 2014 Oct 22. Rheumatology (Oxford). 2015. PMID: 25342376
-
ANCA-associated vasculitis: diagnostic and therapeutic strategy.Allergol Int. 2007 Jun;56(2):87-96. doi: 10.2332/allergolint.R-07-141. Epub 2007 May 1. Allergol Int. 2007. PMID: 17460438 Review.
Cited by
-
Diagnostic delays in systemic vasculitides.Rheumatol Int. 2024 Jun;44(6):1003-1011. doi: 10.1007/s00296-024-05582-9. Epub 2024 Apr 8. Rheumatol Int. 2024. PMID: 38587659 Review.
-
Muscle Vasculitis: A Novel Delineation of Distinct Subsets of Disease.ACR Open Rheumatol. 2025 Jun;7(6):e70062. doi: 10.1002/acr2.70062. ACR Open Rheumatol. 2025. PMID: 40523656 Free PMC article.
-
Granulomatosis with polyangiitis: clinical characteristics and updates in diagnosis.Front Med (Lausanne). 2024 Aug 27;11:1369233. doi: 10.3389/fmed.2024.1369233. eCollection 2024. Front Med (Lausanne). 2024. PMID: 39257888 Free PMC article. Review.
References
-
- Kitching AR, Anders HJ, Basu N. et al. ANCA-associated vasculitis. Nat Rev Dis Primers 2020;6:71. - PubMed
-
- Mohammad AJ. An update on the epidemiology of ANCA-associated vasculitis. Rheumatology (Oxford) 2020;59:iii42–50. - PubMed
-
- Fauci AS, Haynes BF, Katz P, Wolff SM.. Wegener's granulomatosis: prospective clinical and therapeutic experience with 85 patients for 21 years. Ann Intern Med 1983;98:76–85. - PubMed
-
- Yates M, Watts RA, Bajema IM, Cid MC. et al. EULAR/ERA-EDTA recommendations for the management of ANCA-associated vasculitis. Ann Rheum Dis 2016;75:1583–94. - PubMed
-
- de Groot K, Harper L, Jayne DRW. et al. Pulse versus daily oral cyclophosphamide for induction of remission in antineutrophil cytoplasmic antibody-associated vasculitis: a randomized trial. Ann Intern Med 2009;150:670–80. - PubMed
LinkOut - more resources
Full Text Sources
Research Materials
Miscellaneous